Mrs Pamela Suzanne Smith, LMFT | |
621 Chickasaw Dr, Westminster, SC 29693-6409 | |
(478) 972-2882 | |
Not Available |
Full Name | Mrs Pamela Suzanne Smith |
---|---|
Gender | Female |
Speciality | Marriage & Family Therapist |
Location | 621 Chickasaw Dr, Westminster, South Carolina |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1477600997 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
106H00000X | Marriage & Family Therapist | MFT000976 (Georgia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Pamela Suzanne Smith, LMFT Po Box 466, Lavonia, GA 30553-0466 Ph: (478) 474-7177 | Mrs Pamela Suzanne Smith, LMFT 621 Chickasaw Dr, Westminster, SC 29693-6409 Ph: (478) 972-2882 |
News Archive
The brain still harbours many unknowns. Basically, it is assumed that it stores experiences by altering the connections between brain cells. This ability to adapt - which is also called "plasticity" - provides the basis for memory and learning, which is the ability to draw conclusions from memories. On a molecular scale these changes are mediated by modifications of expression of specific genes that as required strengthen or weaken the connections between the brain cells.
How do certain multiple myeloma treatment drugs cause complications? How does the immune system become dysfunctional due to cancer? How safe is a vaccine that could prevent development of precancerous colon polyps? Those are among the many questions that will be answered by researchers from the University of Pittsburgh Cancer Institute and the University of Pittsburgh School of Medicine during the American Association for Cancer Research 102nd Annual Meeting 2011, April 2 to 6, in Orlando, Fla.
Disturbed sleep timing in people living with schizophrenia is more likely to be related to light exposure than to intrinsic biological factors.
In patients with advanced uveal melanoma, treatment with the agent selumetinib, compared with chemotherapy, resulted in an improved cancer progression-free survival time and tumor response rate, but no improvement in overall survival, according to a study in the June 18 issue of JAMA. The modest improvement in clinical outcomes was accompanied by a high rate of adverse events.
› Verified 2 days ago